Menu Back toS16-Promotion-of-Pediatric-Drug-Development-by-Industry-Government-and-Academia-What-Has-Changed-What-Has-Been-Done-and-What-Is-Necessary-for-the-Further-Progress

16th DIA Japan Annual Meeting 2019

Delivering Rational Medicine for All People in the Globe


[S16] Promotion of Pediatric Drug Development by Industry, Government and Academia - What Has Changed, What Has Been Done and What Is Necessary for the Further Progress?

Session Chair(s)

Junko  Sato, PhD

Junko Sato, PhD

  • Director, Office of International Programs
  • Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Varous measures are being created to promote pediatric drug development by industry, government and academia. From this perspective, efforts made in the past 1 year to promote the periatric development will be reviewed, and in the panel, issues surrounding the periatric drug development will be discussed in order to address them. A patient representative will also be invited to the panel discussion to proivde the patient viewpoints.

Speaker(s)

Chitose  Ogawa, MD

New Drug Development for Children’s Cancer - What has been done? What has changed?

Chitose Ogawa, MD

  • Chief, Department of Pediatric Oncology
  • National Cancer Center Hospital, Japan
Michiyo  Sakiyama, MD

Promotion of Pediatric Drug Development –What Has Changed, What Has Been Done and What Is Necessary for the Further Progress? –From the Perspective of the PMDA

Michiyo Sakiyama, MD

  • Associate Senior Scientist for Clinical Medicine, Office of Vaccines and Blood
  • Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Takayuki  Imaeda, MPharm, MS

Pediatric Clinical Development Update at Pfizer Japan

Takayuki Imaeda, MPharm, MS

  • Senior Director, Regulatory Affairs
  • Pfizer R&D Japan, Japan